Vaccine announced that it has notified Nasdaq of its decision to delist the company’s shares of common stock, par value $0.0001 per share, from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.